Table 2.
Median the recurrence-free survival (RFS) rate and hazard ratio (HR) for each risk groupa
| Group | Rotterdam | Okayama | ||||
|---|---|---|---|---|---|---|
| Low | Intermediate | High | Low | Intermediate | High | |
| ERASL-pre | ||||||
| n (%) | 217 (78) | 58 (21) | 4 (1) | 285 (73) | 80 (20) | 27 (7) |
| Median RFS: months (95% CI) |
26 (21–39) |
17 (9–43) |
9 (5–NR) |
100 (60–118) |
14 (11–24) |
4 (3–19) |
| HR (95% CI) | 1 |
1.4 (0.9–2.2) |
2.8 (0.9–8.9) |
1 |
3.0 (2.1–4.3) |
6.2 (3.7–10.4) |
| ERASL-post | ||||||
| n (%) | 163 (63) | 93 (36) | 3 (1) | 286 (73) | 80 (20) | 26 (7) |
| Median RFS: months (95% CI) |
33 (23; 41) |
17 (11–26) |
7 (0.49–NR) |
99 (60–118) |
12 (8–20) |
4 (3–18) |
| HR (95% CI) | 1 |
1.7 (1.1–2.4) |
5.5 (1.7–17.6) |
1 |
3.5 (2.4–5.0) |
6.9 (4.1–11.8) |
ERASL, early recurrence after surgery for liver tumor; CI, confidence interval; NR, not reached
aNumber of patients per risk group, median survival, and the relative risk. The low-risk group was taken as the reference category.